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This summary is not meant to apply to kidney patients who 
are recently post-transplant. These patients are considered 
more significantly immunosuppressed than those who have 
only chronic kidney disease, with or without dialysis. 
Vaccination of Renal Dialysis Patients and Patients with Chronic Renal Disease 
“Patients with renal failure have an increased risk of infection with a variety of pathogens, particularly 
pneumococcus and hepatitis B. The efficacy of pneumococcal vaccination for some of these patients, 
including those on dialysis, may be considerably lower than for immunocompetent patients, their anti­
body levels may be lower, and they may require repeat vaccination or an increased dose of vaccine. 
Because secondary antibody responses are less affected than primary antibody responses, immuniza­
tion strategies should be formulated early in the course of progressive renal disease. This approach is 
particularly important if transplantation and chronic immunosuppressive therapy are being consid­
ered. Nephrotic syndrome is the renal disease most clearly associated with an increased risk for pneu­
mococcal infection.”1 






Hepatitis A X* 
Hepatitis B X (see p. 2) 
Influenza (TIV) X (see p. 3) 
Influenza (LAIV) X (see p. 4) 
Japanese Encephalitis X* 
MMR X* 
Meningococcal X* 
Pneumococcal X (see p. 4) 






Yellow Fever X* 
*No specific ACIP recommendation for this vaccine exists for renal dialysis patients and 
patients with chronic renal disease. 
†Children with primary immunodeficiency disorders and both children and adults who have 
received hematopoietic, hepatic, or renal transplants are at risk for severe or prolonged 
rotavirus gastroenteritis and can shed rotavirus for prolonged periods. [“Prevention of 
Rotavirus Gastroenteritis Among Infants and Children: Recommendations of the Advisory 




Adapted from CDC. Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients. MMWR 
2001;50 (No. RR-5):Table 3 
“If an adult patient begins the vaccine series with a standard dose before beginning 
hemodialysis treatment, then moves to hemodialysis treatment before completing the series, com­
lete the series using the higher dose recommended for hemodialysis patients. No specific recom­
mendations have been made for higher doses for pediatric hemodialysis patients. If a lower than 
recommended vaccine dose is administered to either adults or children, the dose should be 
repeated.”4 
continued . . . 
Hepatitis B Vaccine 
"Hepatitis B vaccination is recommended for all susceptible chronic hemodialysis patients .
. . Vaccination is recommended for pre-end-stage renal disease patients before they become dialy­
sis dependent and for peritoneal and home dialysis patients because they might require in-center 
hemodialysis. 
“Patients with uremia who were vaccinated before they required dialysis have been shown 
to have higher seroconversion rates and antibody titers. The response may also be better in chil-
dren.”2 
Dosage and Schedule 
"For patients undergoing hemodialysis and for other immunosuppressed patients, higher 
vaccine doses or increased number of doses are required. A special formulation of one vaccine is 




Hepatitis B Vaccine, continued 
Immunogenicity and Duration of Immunity 
"Although data concerning the response of pediatric hemodialysis patients to vaccination 
with standard pediatric doses are lacking, protective levels of antibody occur in 75% -97% of 
those who receive higher dosages (20-µg) on either the 3- or the 4-dose schedule."5 
"Limited data are available on the duration of immune memory after hepatitis B vaccina­
tion in . . . dialysis patients. No clinically important HBV infections have been documented 
among immunocompromised persons who maintain protective levels of anti-HBs. . . .However,  
among hemodialysis patients who respond to the vaccine, clinically significant HBV infection has 
been documented in persons who have not maintained anti-HBs concentrations of >10 
mIU/mL."6 
Serologic Testing 
Testing after vaccination is recommended for persons (including hemodialysis patients) 
whose subsequent clinical management depends on knowledge of their immune status. "Testing 
should be performed 1-2 months after administration of the last dose of the vaccine series by 
using a method that allows determination of a protective level of anti-HBs (>10 mIU/mL)." 
"Persons found to have anti-HBs levels of <10 mIU/mL after the primary vaccine series 
should be revaccinated. Administration of three doses on an appropriate schedule . . ., followed 
by anti-HBs testing 1-2 months after the third dose, is usually more practical than serologic test­
ing after one or more doses of vaccine." 
"Persons who do not respond to revaccination should be tested for HBsAg. If the HBsAg 
test result is positive, the persons should receive appropriate management . . . and any household, 
sexual, or needle-sharing contacts should be identified and vaccinated. Persons who test negative 
for HBsAg should be considered susceptible to HBV infection and should be counseled about 
precautions to prevent HBV infection and the need to obtain HBIG postexposure prophylaxis for 
any known or likely parenteral exposure to HBsAg-positive blood."7 
Booster Doses 
"For hemodialysis patients, the need for booster doses should be assessed by annual anti­
body to hepatitis B surface antigen (anti-HBs) testing. A booster dose should be administered 
when anti-HBs levels decline to <10 mIU/mL."8 
Influenza Vaccine 
Inactivated Influenza Vaccine (TIV) 
“The following groups are recommended to receive annual influenza vaccination . . . Persons at 
Increased Risk for Complications . . . adults and children who have required regular medical fol-
low-up or hospitalization during the preceding year because of chronic metabolic diseases (includ­
ing diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including 
immunosuppression caused by medications or by human immunodeficiency virus [HIV]).”9 
continued . . . 
3 
Influenza Vaccine, continued 
Live, Attenuated Influenza Vaccine (LAIV)      CONTRAINDICATED 
“Persons Who Should Not Be Vaccinated with LAIV . . . persons with . . . other underlying med­
ical conditions, including such metabolic diseases as diabetes, renal dysfunction, and hemoglo­
binopathies . . .” “These persons should receive inactivated influenza vaccine.”10 
Use of influenza antivirals for persons with impaired renal function11 
Zanamivir. Limited data are available regarding the safety and efficacy of zanamivir for patients with 
impaired renal function. Among patients with renal failure who were administered a single intravenous dose of 
zanamivir, decreases in renal clearance, increases in half-life, and increased systemic exposure to zanamivir 
were observed. However, a limited number of healthy volunteers who were adminisistered high doses of intra­
venous zanamivir tolerated systemic levels lf zanamivir that were substantially higher than those resulting from 
administration of zanamivir by oral inhalation at the recommended dose. On the basis of these considerations, 
the manufacturer recommends no dose adjustment for inhaled zanamivir for a 5-day course of treatment 
patients with either mild-to-moderate or severe impairment in renal function. 
Oseltamivir. Serum concentrations of oseltamivir carboxylate (GS4071), the active metabolite of oseltamivir, 
increase with declining renal function. For patients with creatinine clearance of 10-30 mL/min, a reduction of 
the treatment dosage of oseltamivir to 75 mg once daily and in the chemoprophylaxis dosage to 75 mg every 
other day is recommended. No treatment or chemoprophylaxis dosing recommendations are avialable for 
patients undergoing routine renal dialysis treatment. 
Pneumococcal Vaccine 
PPV23 
“Vaccination is . . . recommended for immunocompromised adults at increased risk of 
pneumococcal disease or its complications (e.g., persons with splenic dysfunction or anatomic 
asplenia, Hodgkin's disease, leukemia, lymphoma, multiple myeloma, chronic renal failure, 
nephrotic syndrome, or conditions such as organ transplantation associated with immunosuppres-
sion).”12 
Revaccination 
“. . . revaccination once is recommended for persons aged >2 years who are at highest risk 
for serious pneumococcal infection and those who are likely to have a rapid decline in pneumoco­
coccal antibody levels, provided that 5 years have elapsed since receipt of the first dose of pneu­
mococcal vaccine. Revaccination 3 years after the previous dose may be considered for children 
at highest risk for severe pneumococcal infection who would be aged <10 years at the time of 
revaccination. 
Persons at highest risk and those most likely to have rapid declines in antibody levels 
include persons with . . . chronic renal failure, nephrotic syndrome, or other conditions associated 
with immunosuppression (e.g., organ or bone marrow transplantation) . . .”13 
continued . . . 
4 
Pneumococcal Vaccine (PPV23): continued 
Recommendations for use of PPV23 Among Children Previously Vaccinated with PCV7 
“Children who have completed the PCV7 vaccination series before age 2 years and who 
are among risk groups for which PPV23 is already recommended should receive one dose of 
PPV23 at age 2 years (>2 months after the last dose of PCV7). These groups at high risk include 
children with SCD, children with functional or anatomic asplenia, children who are HIV-infected, 
and children who have immunocompromising or chronic diseases. Although data regarding safety 
of PPV23 administered after PCV7 are limited, the opportunity to provide additional serotype 
coverage among these children at very high risk justifies use of the vaccines sequentially.” 14 
PCV7 
(These recommendations apply to children 24-59 months of age. All children 6 months through 
23 months of age should get PCV7 regardless of their health status as part of the routine child­
hood immunization schedule.) 
“Children aged 24-59 months should receive PCV7 vaccination if they are at high risk for 
pneumococcal infection caused by an underlying medical condition. This recommendation 
applies to the following groups: . . .  
- children with immunocompromising conditions, including . . . chronic renal failure or nephrotic 
syndrome.” 
“For children aged 24-59 months with underlying medical conditions . . ., ACIP recom­
mends two doses of PCV7, administered 2 months apart, followed by one dose of PPV23 admin­
istered >2 months after the second dose of PCV7.”15 
Recommendations for Use of PCV7 Among Children Previously Vaccinated with PPV23 
“Children aged 24-59 months who are at high risk for pneumococcal disease and who have 
already received PPV23 (i.e., children with [Sickle Cell Disease], HIV infection, or who have 
other immunocompromising illnesses or chronic diseases) could benefit from the immunologic 
priming and T-cell-dependent immune system response induced by PCV7. Thus, among children 
in these groups at high risk sequential use of the two pneumococcal vaccines can provide addi­
tional protection. Health-care providers should vaccinate children aged 24-59 months at high risk 
who have not previously received PCV7 but who have already received PPV23 with two doses of 
PCV7 administered >2 months apart. Vaccination with PCV7 should be initiated >2 months 
after vaccination with PPV23. Providers should be aware that minimal safety data are available 
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